MediSieve

company

About

MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
£150K
Industries
Biotechnology,Health Care,Medical Device,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
11 - 50
Operating Status
Active

MediSieve is a multi-award-winning medical device company developing Magnetic Blood Filtration (MBF), a platform technology for the treatment of blood-borne diseases by physically removing disease relevant targets directly from a patient’s bloodstream. MBF is an extracorporeal technology, similar to dialysis. A patient's blood is continuously circulated through an external blood loop containing the MediSieve system. Targeted magnetic particles (TB-MPs) are infused into the loop, binding specifically to disease-relevant targets in the patient's blood. The blood then flows through a magnetic filter which captures the particles and bound targets and the remainder of the blood returns to the patient unaffected; the TB-MPs never enter the patient’s body.
MediSieve is based at the Imperial Incubator in White City, London. It has dedicated workshop and laboratory facilities (including capacity for ELISAs, Flow Cytometry and human blood testing) in which products are developed and validated.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
£150K
MediSieve has raised a total of £150K in funding over 2 rounds. Their latest funding was raised on Feb 8, 2018 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 8, 2018 Grant £150K 1 National Institute of Health Research Detail

Investors

Number of Lead Investors
Number of Investors
1
1
MediSieve is funded by 1 investors. National Institute of Health Research are the most recent investors.
Investor Name Lead Investor Funding Round
National Institute of Health Research Yes Grant